Vision Marine Technologies Inc.
VMARDrugs in Pipeline
14
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
Dec 15, 2026
32wMarket Overview
Stock performance and key metrics
1 upcoming, 3 past
rebamipide 2% ophthalmic suspension
Dry Eye Syndromes
Emixustat
Stargardt Disease
Netarsudil Ophthalmic Solution
Fuchs Endothelial Dystrophy
ACU-4429
Dry Age-related Macular Degeneration
GB-102
Diabetic Macular Edema
Drug: GB-102
Neovascular Age-Related Macular Degeneration
Riboflavin
Keratoconus
OPA-6566
Primary Open-angle Glaucoma
Prednisolone acetate
Fuchs' Dystrophy
emixustat hydrochloride
Proliferative Diabetic Retinopathy
SHJ002/Vehicle
Dry Eye Disease
EV06 Ophthalmic Solution
Presbyopia
SHJ002
Corneal Erosion
Atropine
Myopia, Progressive
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
rebamipide 2% ophthalmic suspension | Phase 3 | Dry Eye Syndromes | - | - |
Emixustat | Phase 3 | Stargardt Disease | - | - |
Netarsudil Ophthalmic Solution | Phase 3 | Fuchs Endothelial Dystrophy | - | - |
ACU-4429 | Phase 3 | Dry Age-related Macular Degeneration | - | - |
GB-102 | Phase 2 | Diabetic Macular Edema | - | - |
Drug: GB-102 | Phase 2 | Neovascular Age-Related Macular Degeneration | - | - |
Riboflavin | Phase 2 | Keratoconus | - | - |
OPA-6566 | Phase 2 | Primary Open-angle Glaucoma | - | - |
Prednisolone acetate | Phase 2 | Fuchs' Dystrophy | - | - |
emixustat hydrochloride | Phase 2 | Proliferative Diabetic Retinopathy | - | - |
SHJ002/Vehicle | Phase 2 | Dry Eye Disease | - | - |
EV06 Ophthalmic Solution | Phase 2 | Presbyopia | - | - |
SHJ002 | Phase 2 | Corneal Erosion | - | - |
Atropine | Phase 2 | Myopia, Progressive | - | - |